Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background Several passive surveillance systems reported increased risks of myocarditis or pericarditis, or both, after COVID-19 mRNA vaccination, especially in young men. We used active surveillance from large health-care databases to quantify and enable the direct comparison of the risk of myocarditis or pericarditis, or both, after mRNA-1273 (Moderna) and BNT162b2 (Pfizer–BioNTech) vaccinations. Methods We conducted a retrospective cohort study, examining the primary outcome of myocarditis or pericarditis, or both, identified using the International Classification of Diseases diagnosis codes, occurring 1–7 days post-vaccination, evaluated in COVID-19 mRNA vaccinees aged 18–64 years using health plan claims databases in the USA. Observed (O) incidence rates were compared with expected (E) incidence rates estimated from historical cohorts by each database. We used multivariate Poisson regression to estimate the adjusted incidence rates, specific to each brand of vaccine, and incidence rate ratios (IRRs) comparing mRNA-1273 and BNT162b2. We used meta-analyses to pool the adjusted incidence rates and IRRs across databases. Findings A total of 411 myocarditis or pericarditis, or both, events were observed among 15 148 369 people aged 18–64 years who received 16 912 716 doses of BNT162b2 and 10 631 554 doses of mRNA-1273. Among men aged 18–25 years, the pooled incidence rate was highest after the second dose, at 1·71 (95% CI 1·31 to 2·23) per 100 000 person-days for BNT162b2 and 2·17 (1·55 to 3·04) per 100 000 person-days for mRNA-1273. The pooled IRR in the head-to-head comparison of the two mRNA vaccines was 1·43 (95% CI 0·88 to 2·34), with an excess risk of 27·80 per million doses (–21·88 to 77·48) in mRNA-1273 recipients compared with BNT162b2. Interpretation An increased risk of myocarditis or pericarditis was observed after COVID-19 mRNA vaccination and was highest in men aged 18–25 years after a second dose of the vaccine. However, the incidence was rare. These results do not indicate a statistically significant risk difference between mRNA-1273 and BNT162b2, but it should not be ruled out that a difference might exist. Our study results, along with the benefit–risk profile, continue to support vaccination using either of the two mRNA vaccines. Funding US Food and Drug Administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., Grinberg, T., Auster, O., Dagan, N., Balicer, R. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110737 · Cited by 613
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109730 · Cited by 599 · cited 3×
“…risk of myocarditis or pericarditis after mRNA vaccination compared with expected rates reflect similar findings reported in passive surveillance systems, particularly among younger men in the USA, 4 Canada, 20 and Israel, 2 as well as in observational studies in the UK, 21 Denmark, 10 and the USA.”
ResultGargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., Broder, K. R., Gee, J., Weintraub, E., Shimabukuro, T., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7027e2 · Cited by 587 · cited 1×
“11 Additionally, benefit–risk assessments from the FDA 23 and the Advisory Committee on Immunization Practices 24 concluded that the benefits of COVID-19 vaccination to individual people and at the population level clearly outweigh the risk of myocarditis and pericarditis after mRNA vaccination.”
BackgroundMyocarditis and Pericarditis After Vaccination for COVID-19
Diaz, G. A., Parsons, G. T., Gering, S. K., Meier, A. R., Hutchinson, I. V., & Robicsek, A. (2021) · JAMA · doi:10.1001/jama.2021.13443 · Cited by 430
Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
Marshall, M., Ferguson, I. D., Lewis, P., Jaggi, P., Gagliardo, C., Collins, J. S., Shaughnessy, R., Caron, R., Fuss, C., Corbin, K. J. E., et al. (2021) · Pediatrics · doi:10.1542/peds.2021-052478 · Cited by 367
Cited by
Heidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., Tschöpe, C., Kelle, S., Poland, G. A., Frustaci, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2669 · Cited by 159
Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065687 · Cited by 44
Metadata
- Authors
- Wong, H.-L., Hu, M., Zhou, C. K., Lloyd, P. C., Amend, K. L., Beachler, D. C., Secora, A., McMahill-Walraven, C. N., Lu, Y., Wu, Y., Ogilvie, R. P., Reich, C., Djibo, D. A., Wan, Z., Seeger, J. D., Akhtar, S., Jiao, Y., Chillarige, Y., Do, R., Hornberger, J., Obidi, J., Forshee, R., Shoaibi, A., & Anderson, S. A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 399
- Issue
- 10342
- Pages
- 2191-2199
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4281717376
- Cited by
- 169
- References
- 5
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00791-7
- The paper
- Wong, H.-L., Hu, M., Zhou, C. K., Lloyd, P. C., Amend, K. L., Beachler, D. C., Secora, A., McMahill-Walraven, C. N., Lu, Y., Wu, Y., Ogilvie, R. P., Reich, C., Djibo, D. A., Wan, Z., Seeger, J. D., Akhtar, S., Jiao, Y., Chillarige, Y., Do, R., . . . Anderson, S. A. (2022). Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. The Lancet. https://doi.org/10.1016/s0140-6736(22)00791-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.